코어 임상 분자진단 시장 : 제품 유형별, 기술별, 용도별 - 세계 기회 분석과 산업 예측(2023-2032년)

The core clinical molecular diagnostics market was valued at $4.8 billion in 2022 and is estimated to reach $11.9 billion by 2032, exhibiting a CAGR of 9.50% from 2023 to 2032. Core clinical molecular diagnostics refer to essential techniques and procedures conducted in medical laboratories. They focus on analyzing genetic material (DNA, RNA) and proteins at the molecular level to diagnose diseases and guide treatment decisions. These diagnostics encompass various methodologies such as Polymerase Chain Reaction (PCR), DNA sequencing, Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), and immunohistochemistry (IHC). Core clinical molecular diagnostics play a crucial role in personalized medicine by identifying genetic variations, infectious agents, and biomarkers associated with diseases, enabling tailored patient care and improving clinical outcomes.

The increasing prevalence of diseases and the aging population are major driving forces behind the growing demand for core clinical molecular diagnostics. As populations age, the incidence of chronic and age-related diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders rises significantly. Additionally, the aging demographic is more susceptible to infectious diseases due to weakened immune systems. According to data obtained from the U.S. Census Bureau, in 2021, elderly population in the U.S. accounted for 16.5% of the total population, which is 54 million. Moreover, this number is anticipated to increase to 85.7 million by 2050. In addition, according to the National Cancer Institute, the median age for diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer.

Thus, clinical molecular diagnostics play a critical role in accurately diagnosing these conditions by identifying genetic variations, infectious agents, and biomarkers associated with specific diseases. Their ability to provide precise and timely diagnostic information enables healthcare providers to implement personalized treatment strategies, improving patient outcomes and contributing to more effective disease management in an aging population. As such, the demand for core clinical molecular diagnostics is expected to continue increasing to meet the healthcare needs of aging populations worldwide.

In addition, the rising expenditure in healthcare is indeed a significant driver propelling the growth of the core clinical molecular diagnostics market. As healthcare spending increases globally, there's a greater emphasis on improving diagnostic capabilities to enhance patient care and outcomes. The ability of clinical core molecular diagnostics offers precise and personalized diagnostic information, which aligns well with the growing trend towards precision medicine. With more resources being allocated to healthcare, there's an increased ability and willingness to invest in advanced diagnostic technologies such as PCR, DNA sequencing, and NGS, driving market growth. Additionally, as healthcare systems strive to optimize resource utilization and improve cost-effectiveness, the efficiency and accuracy offered by core clinical molecular diagnostics become increasingly attractive, further fueling market expansion.

The core clinical molecular diagnostics market is segmented on the basis of product type, technique, application, and region. On the basis of product type, the market is segmented into Instruments, reagents and software & services. On the basis of technique, the market is segmented into PCR, nucleic acid sequencing, fluorescence in situ hybridization (FISH), and others. On the basis of application, the market is segmented into infectious diseases, genetic disorders, cancer screening, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).

The major key players that operate in the core clinical molecular diagnostics market are F. Hoffmann-La Roche Ltd., Novartis, Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers, Agilent Technologies, Hologic, Inc. Bio-Rad Laboratories, Inc., Qiagen and bioMerieux. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the core clinical molecular diagnostics market analysis from 2022 to 2032 to identify the prevailing core clinical molecular diagnostics market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the core clinical molecular diagnostics market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global core clinical molecular diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Expanded list for Company Profiles
• Historic market data

Key Market Segments

By Product type

• Instruments
• Reagents
• Software and Services

By Technique

• PCR
• Nucleic Acid Sequencing
• Fluorescence In Situ Hybridization (FISH)
• Others

By Application

• Infectious Disease
• Genetic disorder
• Cancer Screening
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• F. Hoffmann La Roche
• Novartis AG
• Abbott Laboratories
• Becton Dickinson & Company
• Siemens Healthineers AG
• Agilent Technologies, Inc.
• Hologic, Inc.
• BioMerieux SA
• Qiagen NV.
• cepheid ab

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Instruments
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Reagents
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Software and Services
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. PCR
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Nucleic Acid Sequencing
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Fluorescence In Situ Hybridization (FISH)
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Infectious Disease
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Genetic disorder
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Cancer Screening
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Others
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Product type
  • 7.2.3. Market size and forecast, by Technique
  • 7.2.4. Market size and forecast, by Application
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Product type
    • 7.2.5.1.2. Market size and forecast, by Technique
    • 7.2.5.1.3. Market size and forecast, by Application
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Product type
    • 7.2.5.2.2. Market size and forecast, by Technique
    • 7.2.5.2.3. Market size and forecast, by Application
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Product type
    • 7.2.5.3.2. Market size and forecast, by Technique
    • 7.2.5.3.3. Market size and forecast, by Application
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Product type
  • 7.3.3. Market size and forecast, by Technique
  • 7.3.4. Market size and forecast, by Application
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Product type
    • 7.3.5.1.2. Market size and forecast, by Technique
    • 7.3.5.1.3. Market size and forecast, by Application
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Product type
    • 7.3.5.2.2. Market size and forecast, by Technique
    • 7.3.5.2.3. Market size and forecast, by Application
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Product type
    • 7.3.5.3.2. Market size and forecast, by Technique
    • 7.3.5.3.3. Market size and forecast, by Application
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Product type
    • 7.3.5.4.2. Market size and forecast, by Technique
    • 7.3.5.4.3. Market size and forecast, by Application
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Product type
    • 7.3.5.5.2. Market size and forecast, by Technique
    • 7.3.5.5.3. Market size and forecast, by Application
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Product type
    • 7.3.5.6.2. Market size and forecast, by Technique
    • 7.3.5.6.3. Market size and forecast, by Application
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Product type
  • 7.4.3. Market size and forecast, by Technique
  • 7.4.4. Market size and forecast, by Application
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Product type
    • 7.4.5.1.2. Market size and forecast, by Technique
    • 7.4.5.1.3. Market size and forecast, by Application
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Product type
    • 7.4.5.2.2. Market size and forecast, by Technique
    • 7.4.5.2.3. Market size and forecast, by Application
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Product type
    • 7.4.5.3.2. Market size and forecast, by Technique
    • 7.4.5.3.3. Market size and forecast, by Application
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Product type
    • 7.4.5.4.2. Market size and forecast, by Technique
    • 7.4.5.4.3. Market size and forecast, by Application
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Product type
    • 7.4.5.5.2. Market size and forecast, by Technique
    • 7.4.5.5.3. Market size and forecast, by Application
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Product type
    • 7.4.5.6.2. Market size and forecast, by Technique
    • 7.4.5.6.3. Market size and forecast, by Application
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Product type
  • 7.5.3. Market size and forecast, by Technique
  • 7.5.4. Market size and forecast, by Application
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Product type
    • 7.5.5.1.2. Market size and forecast, by Technique
    • 7.5.5.1.3. Market size and forecast, by Application
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Product type
    • 7.5.5.2.2. Market size and forecast, by Technique
    • 7.5.5.2.3. Market size and forecast, by Application
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Product type
    • 7.5.5.3.2. Market size and forecast, by Technique
    • 7.5.5.3.3. Market size and forecast, by Application
    • 7.5.5.4. Rest Of La
    • 7.5.5.4.1. Market size and forecast, by Product type
    • 7.5.5.4.2. Market size and forecast, by Technique
    • 7.5.5.4.3. Market size and forecast, by Application
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Product type
  • 7.6.3. Market size and forecast, by Technique
  • 7.6.4. Market size and forecast, by Application
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Product type
    • 7.6.5.1.2. Market size and forecast, by Technique
    • 7.6.5.1.3. Market size and forecast, by Application
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Product type
    • 7.6.5.2.2. Market size and forecast, by Technique
    • 7.6.5.2.3. Market size and forecast, by Application
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Product type
    • 7.6.5.3.2. Market size and forecast, by Technique
    • 7.6.5.3.3. Market size and forecast, by Application
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Product type
    • 7.6.5.4.2. Market size and forecast, by Technique
    • 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. F. Hoffmann La Roche
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Novartis AG
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Abbott Laboratories
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Becton Dickinson & Company
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Siemens Healthineers AG
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Agilent Technologies, Inc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Hologic, Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. BioMerieux SA
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Qiagen NV.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. cepheid ab
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments